Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SELLAS Life Sciences Group (SLS)
NASDAQ:SLS
RESEARCH TOOLSreports
SELLAS Life Sciences Group (SLS) Stock Price & Analysis
802 Followers
SLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $1.91
Previous Close$1.36
Volume1.21M
Average Volume (3M)1.40M
Market Cap
$74.84M
Enterprise Value$71.48M
Total Cash (Recent Filing)$4.00M
Total Debt (Recent Filing)$644.00K
Price to Earnings (P/E)-1.0
Beta1.98
Next Earnings
May 09, 2024EPS EstimateN/A
Last Dividend Ex-Date
Apr 27, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding56,267,670
10 Day Avg. Volume1,596,344
30 Day Avg. Volume1,395,023
Standard Deviation0.34
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-13.13
Price to Sales (P/S)74.84
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit79.42
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$5.75Price Target Upside322.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SELLAS Life Sciences Group News
Ownership Overview
8.10% Insiders
2.52% Mutual Funds
2.76% Other Institutional Investors
86.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLS FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was $0.50 and its highest was $1.91 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
Currently, no data Available
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Mar 28, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of $0.087 by -$0.317.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group pays a Notavailable dividend of $7025.8 which represents an annual dividend yield of N/A. See more information on SELLAS Life Sciences Group dividends here
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 56,267,670 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -$0.23 in its last earnings report, missing expectations of $0.087. Following the earnings report the stock price went up 5.941%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at N/A.
---
SELLAS Life Sciences Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.75 (322.79% Upside)
$5.75 (322.79% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-69.69%
Trailing 12-Months
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
---
SLS Stock 12 Months Forecast
Average Price Target
$5.75
▲(322.79% Upside)
Technical Analysis
Best Analysts Covering SLS
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-12.69%
reiterated a buy rating 19 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -12.69% per trade.
---